Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080002
Status:
TERMINATED
Last Update Posted:
2012-09-06
First Post:
2004-03-19
Brief Title:
Efficacy of Pegamotecan PEG-Camptothecin in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
Sponsor:
Enzon Pharmaceuticals Inc
Organization:
Enzon Pharmaceuticals Inc
Study Overview
Official Title:
Effectiveness and Safety Study of Pegamotecan PEG-Camptothecin in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastroesophageal Junction Who Have Relapsed or Progressed Following a Previous Chemotherapy Treatment
Status:
TERMINATED
Status Verified Date:
2005-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of pegamotecan PEG-camptothecin in patients with pathologically-diagnosed locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction who have relapsed or progressed following one prior chemotherapy treatment regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None